MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
5.35
-0.26
-4.63%
After Hours: 5.32 -0.03 -0.56% 17:47 04/19 EDT
OPEN
5.59
PREV CLOSE
5.61
HIGH
5.79
LOW
5.31
VOLUME
7.29K
TURNOVER
0
52 WEEK HIGH
8.85
52 WEEK LOW
2.780
MARKET CAP
29.05M
P/E (TTM)
-1.3547
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at APRE last week (0408-0412)?
Weekly Report · 6d ago
Aprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Rating
TipRanks · 04/12 15:35
Optimistic Outlook for Aprea Therapeutics’ Oncology Pipeline: A Comprehensive Buy Rating Analysis
TipRanks · 04/11 10:26
Aprea Therapeutics Announces Presentations On Its Next Generation WEE1 Inhibitor, APR-1051, And A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for cyclin E-overexpressing cancers. APR- 1051 has received FDA clearance for a first in human trial. Company also presented four poster presentations at the American Association of Cancer Research Annual Meeting.
Benzinga · 04/10 16:02
Weekly Report: what happened at APRE last week (0401-0405)?
Weekly Report · 04/08 10:53
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Tevogen Bio Holdings stock rose 85.5% to $4.86 during Thursday's pre-market session. Candel Therapeutics (NASDAQ:CADL) shares rose 27.97% and Healthcare Triangle stock rose 23.56% in the same session. Losers Telesis Bio (NASdaq:TBIO) stock fell 11.8% during the session. Q4 earnings came out today.
Benzinga · 04/04 12:09
Aprea Therapeutics files to sell 4.39M shares of common stock for holders
Seeking Alpha · 04/03 20:30
APREA THERAPEUTICS INC FILES FOR SHELF OF UP TO 4.4 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 04/03 20:08
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. It has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The Company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.